Loading
Lung Cancer Treatments and Mutations · Journal article
Cell Communication and Signaling · August 14, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review that synthesizes current knowledge of TTK (Mps1) function in cancer biology, emphasizing its paradoxical roles in both safeguarding genomic stability and supporting tumor adaptation under chromosomal instability. The review identifies emerging mechanistic insights and highlights critical unresolved questions, but does not report primary clinical or preclinical trial data to support definitive conclusions about therapeutic efficacy or clinical impact.
Narrative review. Cancer cells with elevated chromosomal instability; clinical studies mentioned but not detailed.
TTK is frequently overexpressed across a wide range of cancers and supports tumor cell survival under elevated chromosomal instability Pharmacological inhibition of TTK induces mitotic catastrophe by exacerbating chromosome mis-segregation, selectively targeting cancer cells Several small-molecule TTK inhibitors have entered clinical evaluation, particularly in combination with chemotherapeutic agents and radiotherapy
No data on adverse effects, tolerability, or comparative efficacy of TTK inhibitors versus standard therapy Pharmacological inhibition of TTK induces mitotic catastrophe by exacerbating chromosome mis-segregation, selectively targeting cancer cells
This review identifies TTK as a potential therapeutic target and signals that multiple TTK inhibitors are entering clinical development. However, it emphasizes that heterogeneous therapeutic responses, unresolved mechanistic questions, and gaps in understanding tumor selectivity currently limit clinical translation; clinicians should await results from ongoing trials and biomarker studies before incorporating TTK inhibition into routine practice.
This is a narrative review consolidating existing knowledge and raising unresolved mechanistic questions about TTK biology in cancer; it does not present primary experimental data, clinical trial results, or definitive evidence to support practice changes.
As stated by the source record.
This review identifies TTK as a potential therapeutic target and signals that multiple TTK inhibitors are entering clinical development. However, it emphasizes that heterogeneous therapeutic responses, unresolved mechanistic questions, and gaps in understanding tumor selectivity currently limit clinical translation; clinicians should await results from ongoing trials and biomarker studies before incorporating TTK inhibition into routine practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Abstract Threonine tyrosine kinase (TTK) also known as MonoPolar Spindle 1 (Mps1) is a core regulator of the spindle assembly checkpoint (SAC) that ensures accurate chromosome segregation during mitosis. While its canonical role in safeguarding genomic stability is well established, emerging evidence indicates that TTK is frequently overexpressed across a wide range of cancers, where it supports tumor cell survival under conditions of elevated chromosomal instability (CIN). This paradox highlights TTK's dual role as both a guardian of mitotic fidelity and a facilitator of tumor adaptability. Recent studies have demonstrated that pharmacological inhibition of TTK induces mitotic catastrophe by exacerbating chromosome mis-segregation, thereby selectively targeting cancer cells. Several small-molecule TTK inhibitors have entered clinical evaluation, particularly in combination with chemotherapeutic agents and radiotherapy. However, therapeutic responses remain heterogeneous, and the mechanistic basis of tumor-specific reliance on TTK across different cancer contexts remains poorly understood. This review consolidates current knowledge of TTK function beyond its canonical SAC activity, emphasizing its emerging roles in DNA damage response, epithelial-mesenchymal transition, and oncogenic signaling pathways. In addition, the review highlights critical unresolved questions, including the distinction between kinetochore and non-kinetochore functions, and the quantitative thresholds of TTK activity required for checkpoint maintenance. Finally, current advances in TTK-targeted drug development, challenges related to therapeutic selectivity and resistance, along with rational combination therapies and biomarker-guided therapeutic strategies have been summarized. Addressing these challenges will be critical for translating TTK biology into effective therapeutic interventions and for harnessing its potential in precision oncology.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.